The DOI matches its Crossref record.
A Prospective, Multicenter, Phase I Matched-Comparison Group Trial of Safety, Pharmacokinetics, and Preliminary Efficacy of Riluzole in Patients with Traumatic Spinal Cord Injury
Open accessAbstract
A prospective, multicenter phase I trial was undertaken by the North American Clinical Trials Network (NACTN) to investigate the pharmacokinetics and safety of, as well as obtain pilot data on, the effects of riluzole on neurological outcome in acute spinal cord injury (SCI). Thirty-six patients, with ASIA impairment grades A-C (28 cervical and 8 thoracic) were enrolled at 6 NACTN sites between April 2010 and June 2011. Patients received 50 mg of riluzole PO/NG twice-daily, within 12 h of SCI, for 14 days. Peak and trough plasma concentrations were quantified on days 3 and 14. Peak plasma concentration (Cmax) and systemic exposure to riluzole varied significantly between patients. On the same dose basis, Cmax did not reach levels comparable to those in patients with amyotrophic lateral sclerosis. Riluzole plasma levels were significantly higher on day 3 than on day 14, resulting from a lower clearance and a smaller volume of distribution on day 3. Rates of medical complications, adverse events, and progression of neurological status were evaluated by comparison with matched patients in the NACTN SCI Registry. Medical complications in riluzole-treated patients occurred with incidences similar to those in patients in the comparison group. Mild-to-moderate increase in liver enzyme and bilirubin levels were found in 14-70% of patients for different enzymes. Three patients had borderline severe elevations of enzymes. No patient had elevated bilirubin on day 14 of administration of riluzole. There were no serious adverse events related to riluzole and no deaths. The mean motor score of 24 cervical injury riluzole-treated patients gained 31.2 points from admission to 90 days, compared to 15.7 points for 26 registry patients, a 15.5-point difference (p=0.021). Patients with cervical injuries treated with riluzole had more-robust conversions of impairment grades to higher grades than the comparison group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ahuja, C. S., Wilson, J. R., Nori, S., Kotter, M. R. N., Druschel, C., Curt, A., & Fehlings, M. G. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.18 · Cited by 2,441
Self-citationSpinal cord injury: molecular mechanisms and therapeutic interventions
Hu, X., Xu, W., Ren, Y., Wang, Z., He, X., Huang, R., Ma, B., Zhao, J., Zhu, R., & Cheng, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01477-6 · Cited by 770
Restoring function after spinal cord injury: towards clinical translation of experimental strategies
Ramer, L. M., Ramer, M. S., & Bradbury, E. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70144-9 · Cited by 324
Badhiwala, J. H., Ahuja, C. S., & Fehlings, M. G. (2019) · Journal of Neurosurgery: Spine · doi:10.3171/2018.9.spine18682 · Cited by 288
Self-citation
Metadata
- Authors
- Grossman, R. G., Fehlings, M. G., Frankowski, R. F., Burau, K. D., Chow, D. S. L., Tator, C., Teng, A., Toups, E. G., Harrop, J. S., Aarabi, B., Shaffrey, C. I., Johnson, M. M., Harkema, S. J., Boakye, M., Guest, J. D., & Wilson, J. R.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2014-02
- Volume
- 31
- Issue
- 3
- Pages
- 239-255
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2014263842
- Cited by
- 224
- References
- 0
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective, Multicenter, Phase I Matched-Comparison Group Trial of Safety, Pharmacokinetics, and Preliminary Efficacy of Riluzole in Patients with Traumatic Spinal Cord Injury. https://app.cochat.ai/papers/10.1089/neu.2013.2969
- The paper
- Grossman, R. G., Fehlings, M. G., Frankowski, R. F., Burau, K. D., Chow, D. S. L., Tator, C., Teng, A., Toups, E. G., Harrop, J. S., Aarabi, B., Shaffrey, C. I., Johnson, M. M., Harkema, S. J., Boakye, M., Guest, J. D., & Wilson, J. R. (2014). A Prospective, Multicenter, Phase I Matched-Comparison Group Trial of Safety, Pharmacokinetics, and Preliminary Efficacy of Riluzole in Patients with Traumatic Spinal Cord Injury. Journal of Neurotrauma. https://doi.org/10.1089/neu.2013.2969
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.